First-line treatment of milder forms of psoriasis will continue to be with cheaper, topical medications. Use of more expensive, systemic therapies will continue to be relegated to more severe psoriasis. 

While the psoriasis market will see downward pressure from the arrival of biosimilars of the key marketed anti-TNF brands Enbrel and Humira, overall growth will be driven partly by the recent launches of a number of more targeted and efficacious interleukin inhibitors that have expanded the market, as well as by increasing disease prevalence. 

This Datamonitor Healthcare report contains a Disease Analysis module.